# Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

> **NCT00842348** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 89 (actual)

## Conditions studied

- Non Functioning Entero-pancreatic Endocrine Tumour

## Interventions

- **DRUG:** lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00842348
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00842348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00842348, "Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00842348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*